
FDMT Technical Analysis Summary (NASDAQ)
Analyze FDMT on the NASDAQ with RSI, MACD, ADX, Bollinger Bands, support, resistance, momentum, and the latest technical trading signals.
Disclaimer for Technical Analysis Page
The technical indicators and trading signals shown on this page are for informational purposes only and do not constitute financial advice. Stock market investments involve risk, and past performance is not a guarantee of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.Read our Full DisclaimerFDMT Technical Analysis Summary (NASDAQ)
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) stock currently shows a bullish trend on the NASDAQ, supported by momentum and strong buying pressure.
Technical conditions suggest 4D Molecular Therapeutics, Inc. on the NASDAQ is awaiting a decisive move. Overall, 4D Molecular Therapeutics, Inc. remains neutral, with indicators showing mixed momentum.
RSI (14): 61.07
Stochastic %K: 61.98
Williams %R: -17.09
Rate of Change (ROC): 3.75
Takeaway:4D Molecular Therapeutics, Inc. shows strong bullish momentum, with buyers firmly in control.
MACD: 0.34
ADX: 22.15
ATR (14): 0.94
CCI (14): 146.31
Takeaway:4D Molecular Therapeutics, Inc. shows a firm trend supported by momentum, though one signal suggests caution.
Takeaway:4D Molecular Therapeutics, Inc. trades closer to resistance, supported by stronger momentum within bands.
Takeaway:4D Molecular Therapeutics, Inc. trades above the trend line, showing healthy momentum within the channel.
Overall Takeaway:FDMT shows bullish money flow, with volume and vigor supporting buyers.
Bullish Signals
RSI above 50 → positive momentum from buyers.
MACD above 0 → bullish trend confirmation.
ADX above 20 → strong underlying trend.
Price trading above middle Bollinger Band → mid-term support intact.
MFI below 80 → room for more buying without overbought risk.
Bearish Signals
MACD below signal line → short-term caution on momentum.
Overall Recommendation:Technical indicators for 4D Molecular Therapeutics, Inc. are mixed, suggesting a Hold or wait-and-see approach.